Recent Updates
Recently added Catalysts

VSJ-110

Phase 2

Allergic Conjunctivitis | Small molecule | Ophthalmology |Vanda Pharmaceuticals Inc.|Last Updated: Sep 17, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment47
FDA Designations
No designations recorded
Clinical trial landscape

VSJ-110 · 2 trials · 2 indications

Phase 2 2
NCT07179055An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeDry Eye
RECRUITING160 Analytics
NCT04622345Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesAllergic Conjunctivitis
COMPLETED47 Analytics
PHASE2RECRUITING
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Dry Eye
NCT07179055160
Unlock trial analytics
PHASE2COMPLETED
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Allergic Conjunctivitis
NCT0462234547
Unlock trial analytics
Study Endpoints
Primary Endpoints
Corneal Staining
Measured over an 8-week treatment period

Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.

Ocular Itching as Measured by Self-reported Numerical Scales
16 hours, 8 hours, and 15 minutes post-treatment

Change from baseline in ocular itching evaluated by the subject at 3(±1), 5(±1), and 7(±1) minutes post allergen challenge (0-4 scale, with a higher number indicating more itching)

Conjunctival Redness as Measured by Investigator Assessed Numerical Scales
16 hours, 8 hours, and 15 minutes post-treatment

Change from baseline in conjunctival redness evaluated by the investigator at 7 (±1), 15 (±1), and 20 (±1) minutes post allergen challenge (0-4 scale, with a higher number indicating more redness)

Secondary Endpoints
Schirmer's Tear Test
Measured over an 8-week treatment period
Eye Dryness Score (EDS) of the Visual Analogue Scale (VAS)
Measured over an 8-week treatment period
Conjunctival Redness Responder Rates as Evaluated by the Investigator Using Numerical Scales
16 hours, 8 hours, and 15 minutes post-treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
VSJ-110 SolutionEXPERIMENTAL -
Placebo SolutionPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
VSJ-110DRUGophthalmic solution
PlaceboDRUGophthalmic solution
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the wash...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07179055primaryCompletionDate: changed
LOWMay 24, 2026NCT07179055studyFirstPostDate: changed